MARKET

NXTS

NXTS

Nexentis Technologies Inc
NASDAQ
3.640
-0.170
-4.46%
After Hours: 3.530 -0.11 -3.02% 19:59 07/10 EDT
OPEN
3.790
PREV CLOSE
3.810
HIGH
3.790
LOW
3.580
VOLUME
16.40K
TURNOVER
--
52 WEEK HIGH
89.79
52 WEEK LOW
3.310
MARKET CAP
5.29M
P/E (TTM)
-0.0754
1D
5D
1M
3M
1Y
5Y
1D
Nexentis Technologies Subsidiary Completes Analysis Of SLC Transport Proteins, Starts Global AI Drug Discovery Initiative With Boltz
Benzinga · 5d ago
Nexentis unit MitoCareX Bio expands SLC transporter analysis for drug discovery
PUBT · 5d ago
Weekly Report: what happened at NXTS last week (0629-0703)?
Weekly Report · 6d ago
Nexentis Technologies announces monetization of Melz solar investment
TipRanks · 06/29 12:45
Nexentis Technologies Amends Its Loan And Partnership Agreement With Solterra Renewable Energy, Other Lenders For Melz Solar Project; Solterra To Make Early Partial Repayments Of ~$147K On Its Part Of Loan, $98K For Sale Of 10% Of Its Profit Rights;
Benzinga · 06/29 12:25
NEXENTIS ANNOUNCES MONETIZATION OF PART OF ITS MELZ SOLAR INVESTMENT AT $14.5 MILLION PROJECT VALUATION – SIGNIFICANT PREMIUM TO INITIAL INVESTMENT
Reuters · 06/29 12:21
Nexentis monetizes part of Melz solar investment at USD 14.5 million valuation
PUBT · 06/29 12:20
Weekly Report: what happened at NXTS last week (0622-0626)?
Weekly Report · 06/29 09:35
More
About NXTS
Nexentis Technologies Inc, formerly known as N2OFF, Inc., is an AI and data-driven computational biotech platform focused on mitochondrial biology, precision oncology and inflammatory metabolic diseases. Through its subsidiary MitoCareX Bio Ltd. The company uses a proprietary discovery engine targeting the mitochondrial SLC25 carrier family using its MITOLINE algorithm and structure guided virtual screening workflows. MITOLINE, its proprietary computational platform, is designed to allow proper homology modeling of mitochondrial membrane proteins, particularly transport proteins. It enables three-dimensional structural modeling and large-scale virtual screening, MITOLINE opens access to a novel untapped target space, allowing the Company to identify small-molecule modulators that directly disrupt cancer metabolism with the potential of minimizing systemic toxicity.

Webull offers Nexentis Technologies Inc stock information, including NASDAQ: NXTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NXTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NXTS stock methods without spending real money on the virtual paper trading platform.